The next-generation BTK inhibitor zanubrutinib could be a potential treatment option for treatment naïve chronic lymphocytic leukemia and 17p deletion, results from the Australian-led SEQUOIA trial show. Lead investigator Professor Con Tam from the Peter MacCallum Cancer Centre, Melbourne, notes that patients with CLL or small lymphocytic lymphoma with deletion of chromosome 17p13.1 [del(17p)] respond ...
BTKi shows potential in untreated CLL with del(17p): SEQUOIA
By Nicola Garrett
22 Oct 2020